<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Digoxin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00390</strong>&#160; (APRD00098)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone digoxigenin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00390/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00390/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00390.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00390.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00390.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00390.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00390.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00390">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>12&#946;-hydroxydigitoxin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IUPAC</td></tr><tr><td>Digazolan</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Digossina</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCIT</td></tr><tr><td>Digoxin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>JAN, BAN, BP 2011, JP XV, Ph. Eur. 7, Ph. Int. 4, USP 34</td></tr><tr><td>Digoxina</td><td>Spanish</td><td>INN</td></tr><tr><td>Digoxine</td><td>French</td><td>INN</td></tr><tr><td>Digoxinum</td><td>Latin</td><td>INN</td></tr><tr><td>Lanadicor</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Agoxin</td><td>Aristopharma</td></tr><tr><td>Cardiacin</td><td>Center</td></tr><tr><td>Cardiogoxin</td><td>Medipharma</td></tr><tr><td>Cardioxin</td><td>Oboi</td></tr><tr><td>Cardoxin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Celoxin</td><td>Celon</td></tr><tr><td>Centoxin</td><td>Opsonin</td></tr><tr><td>Digacin</td><td>mibe</td></tr><tr><td>Digitek</td><td>Mylan</td></tr><tr><td>Digocard-G</td><td>Klonal</td></tr><tr><td>DIGOX</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Digoxina</td><td>GlaxoSmithKline</td></tr><tr><td>Eudigox</td><td>Teofarma</td></tr><tr><td>Lanacordin</td><td>Kern</td></tr><tr><td>Lanacrist</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lanicor</td><td>Roche</td></tr><tr><td>Lanoxicaps</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lanoxin</td><td>GlaxoSmithKline</td></tr><tr><td>Lenoxin</td><td>GlaxoSmithKline</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li>
<li><a href="/mesh/anti-arrhythmia-agents">Anti-Arrhythmia Agents</a></li>
<li><a href="/mesh/cardiotonic-agents">Cardiotonic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>20830-75-5</td></tr><tr><th>Weight</th><td>Average: 780.9385<br>Monoisotopic: 780.429606756</td></tr><tr><th>Chemical Formula</th><td>C<sub>41</sub>H<sub>64</sub>O<sub>14</sub></td></tr><tr><th>InChI Key</th><td>LTMHDMANZUZIPE-PUGKRICDSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-2,5-dihydrofuran-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Steroid Lactones</td></tr><tr><th>Direct parent</th><td>Cardenolide Glycosides and Derivatives</td></tr><tr><th>Alternative parents</th><td>Trihexoses; Steroidal Glycosides; Hydroxysteroids; O-glycosyl Compounds; Cyclohexanols; Oxanes; Butenolides; Tertiary Alcohols; 1,2-Diols; Carboxylic Acid Esters; Cyclic Alcohols and Derivatives; Acetals; Polyamines</td></tr><tr><th>Substituents</th><td>steroidal glycoside; 12-hydroxy-steroid; 14-hydroxy-steroid; trisaccharide; glycosyl compound; o-glycosyl compound; cyclohexanol; 2-furanone; saccharide; oxane; tertiary alcohol; cyclic alcohol; dihydrofuran; secondary alcohol; carboxylic acid ester; 1,2-diol; ether; acetal; polyamine; carboxylic acid derivative; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.</td></tr><tr><th>Pharmacodynamics</th><td>Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.</td></tr><tr><th>Mechanism of action</th><td>Digoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX)in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.</td></tr><tr><th>Absorption</th><td>Absorption of digoxin from the elixir pediatric formulation has been demonstrated to be 70% to 85% complete (90% to 100% from the capsules, and 60% to 80% for tablets).</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>25%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic (but not dependent upon the cytochrome P-450 system). The end metabolites, which include 3 b-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Digoxin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00697">3 b-digoxigenin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/718">Details</a></td></tr><tr><td>Digoxin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00716">3-keto-digoxigenin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/737">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Following intravenous administration to healthy volunteers, 50% to 70% of a digoxin dose is excreted unchanged in the urine.</td></tr><tr><th>Half life</th><td>3.5 to 5 days</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Toxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD<sub>50</sub> = 7.8 mg/kg (orally in mice).</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.941</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.7241</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8586</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5325</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6209</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8621</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.855</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7366</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9261</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9196</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9359</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9385</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9279</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9279</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9233
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9668
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9555
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          4.4721 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9818
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8051
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Glaxosmithkline llc</li>
<li>Roxane laboratories inc</li>
<li>Abraxis pharmaceutical products</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Hospira inc</li>
<li>Sandoz canada inc</li>
<li>Wyeth ayerst laboratories</li>
<li>Actavis totowa llc</li>
<li>Caraco pharmaceutical laboratories ltd</li>
<li>Impax laboratories inc</li>
<li>Jerome stevens pharmaceuticals inc</li>
<li>West ward pharmaceutical corp</li>
<li>Smithkline beecham corp dba glaxosmithkline</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li>C.O. Truxton Inc.</li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Dept Health Central Pharmacy</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.draxispharma.com">Draxis Specialty Pharmaceuticals Inc.</a></li>
<li><a href="http://www.dsm.com">DSM Corp.</a></li>
<li><a href="http://www.duramed.ca">Duramed</a></li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li>Jerome Stevens Pharmaceuticals Inc.</li>
<li>Kaiser Foundation Hospital</li>
<li>Kraft Pharmaceutical Co. Inc.</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lannett.com">Lannett Co. Inc.</a></li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.savagelabs.com">Savage Labs</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li>Talbert Medical Management Corp.</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00284">Acarbose</a></td><td>Acarbose may decrease the serum levels of digoin. It is thought that acarbose reduces digoin absorption. Monitor for changes in digoxin serum levels and therapeutic and adverse effects if acarbose is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>The benzodiazepine, alprazolam, may increase the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may increase the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB00436">Bendroflumethiazide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00562">Benzthiazide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00290">Bleomycin</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB06616">Bosutinib</a></td><td>Bosutinib is a substrate and inhibitor of p-glycoprotein (p-gp) and may increase levels of other p-gp substrates. </td></tr><tr><td><a href="/drugs/DB00887">Bumetanide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB08907">Canagliflozin</a></td><td>When coadministered with 300 mg canagliflozin, the AUC and mean peak drug concentration of digoxin increased. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00262">Carmustine</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Carvedilol may increase the serum levels and effect of digoxin.</td></tr><tr><td><a href="/drugs/DB00880">Chlorothiazide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00310">Chlorthalidone</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB01432">Cholestyramine</a></td><td>The resin decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB08810">Cinitapride</a></td><td>Cinitapride can alter the absorption of digoxin as it simulates gastric emptying.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the effect of digoxin in 10% of patients.</td></tr><tr><td><a href="/drugs/DB00375">Colestipol</a></td><td>The resin decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00531">Cyclophosphamide</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Cyclosporine may increase the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB00606">Cyclothiazide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00987">Cytarabine</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00509">Dextrothyroxine</a></td><td>The thyroid hormone, dextrothyroxine, decreases the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>The benzodiazepine, diazepam, may increase the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>Quinine/quinidine increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00997">Doxorubicin</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of digoxin 2.5-fold. </td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients.</td></tr><tr><td><a href="/drugs/DB00903">Ethacrynic acid</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Digoxin, when administered concomitantly with etravirine, may experience an increase in serum concentration. It is recommended to monitor serum levels of digoxin and titrate dosage to achieve desired therapeutic range. Pre-emptive dose adjustments are not required.</td></tr><tr><td><a href="/drugs/DB00695">Furosemide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB01044">Gatifloxacin</a></td><td>Gatifloxacin increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB01404">Ginseng</a></td><td>Changes in digoxin serum levels</td></tr><tr><td><a href="/drugs/DB00999">Hydrochlorothiazide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00774">Hydroflumethiazide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB01611">Hydroxychloroquine</a></td><td>Hydroxychloroquine increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00808">Indapamide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The macrolide, josamycin, may increase the effect of digoxin in 10% of patients.</td></tr><tr><td><a href="/drugs/DB00451">Levothyroxine</a></td><td>The thyroid hormone, levothyroxine, decreases the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB00279">Liothyronine</a></td><td>The thyroid hormone, liothyronine, decreases the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB01583">Liotrix</a></td><td>The thyroid hormone, liotrix, decreases the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB06655">Liraglutide</a></td><td>These agents may have decreased C max and a delayed T max during coadministration.</td></tr><tr><td><a href="/drugs/DB00763">Methimazole</a></td><td>The antithyroid agent increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00232">Methyclothiazide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00524">Metolazone</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB04896">Milnacipran</a></td><td>Use of Savella concomitantly with digoxin may be associated with potentiation of adverse hemodynamic effects. Co-administration of Savella and intravenous digoxin should be avoided. </td></tr><tr><td><a href="/drugs/DB08893">Mirabegron</a></td><td>Mirabegron increased Cmax and AUC of digoxin. Initiate therapy with digoxin at lowest possible dose. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.</td></tr><tr><td><a href="/drugs/DB00299">Penciclovir</a></td><td>The multivalent agent decreases the effect of penicillamine</td></tr><tr><td><a href="/drugs/DB00859">Penicillamine</a></td><td>Penicillamine decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB01324">Polythiazide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00457">Prazosin</a></td><td>Prazosin increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB01168">Procarbazine</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Propafenone increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00550">Propylthiouracil</a></td><td>The antithyroid agent may increase the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB01325">Quinethazone</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Quinine/quinidine increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Quinine/quinidine increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00468">Quinine</a></td><td>Quinine/quinidine increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB01129">Rabeprazole</a></td><td>Rabeprazole increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Ranolazine may increase the serum level of digoxin. Monitor for changes in the serum level and therapeutic and adverse effects of digoxin if ranolazine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir increases levels/effect of digoxin</td></tr><tr><td><a href="/drugs/DB00421">Spironolactone</a></td><td>Increased digoxin levels and decreased effect in presence of spironolactone</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00795">Sulfasalazine</a></td><td>Sulfasalazine may decrease the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir is a substrate of p-glycoprotein and thus increases the AUC and Cmax of digoxin. This indicates an increased absorption of digoxin. Lowest dose of digoxin should be used first and levels be closely monitored. 
</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may increase the plasma concentration of Digoxin. Monitor for changes in Digoxin efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Telmisartan may increase plasma Digoxin concentrations. Monitor Digoxin levels and adjust dose as required if Telmisartan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01584">Thyroglobulin</a></td><td>The thyroid hormone, thyroglobulin, decreases the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine may decrease Digoxin levels. Monitor for Digoxin levels with Ticlopidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Tolvaptan increases serum digoxin concentrations due to competitive inhibition of P-glycoprotein in the liver, intestine, and kidney. P-glycoprotein facilitates digoxin efflux thus inhibition of this protein will increase incidence of adverse effects. </td></tr><tr><td><a href="/drugs/DB01021">Trichlormethiazide</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB01157">Trimetrexate</a></td><td>The absorption of Digoxin, a cardiac glycoside, may be decreased by antineoplastic agents such as Trimetrexate. Liquid forms of Digoxin do not appear to be significantly affected. Monitor Digoxin tablet efficacy if Trimetrexate therapy is initiated, discontinued or if the dose is altered.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil may increase the serum concentration of Digoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digoxin if Verpamail is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole may increase the serum concentration of digoxin. Monitor for increased serum concentrations and toxic effects of digoxin if voriconazole is initiated or dose increased.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid avocado.</li>
<li>Avoid bran and high fiber foods within 2 hours of taking this medication.</li>
<li>Avoid excess salt/sodium unless otherwise instructed by your physician.</li>
<li>Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.</li>
<li>Avoid salt substitutes containing potassium.</li>
<li>Limit garlic, ginger, gingko, and horse chestnut.</li></ul></td></tr></tbody></table>